Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells $44,065.18 in Stock

SiBone logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Laura Francis sold 1,901 SiBone shares for $44,065, with the proceeds used to cover tax withholding on vested equity awards. She retained 351,275 shares after the sale.
  • SiBone reported quarterly EPS of -$0.08, beating analyst estimates of -$0.13, and revenue of $55.7 million, slightly above expectations.
  • Analysts maintain a “Moderate Buy” consensus rating and a $25 average price target; seven rate the stock Buy and one rates it Sell.
  • Interested in SiBone? Here are five stocks we like better.

SiBone (NASDAQ:SIBN - Get Free Report) CEO Laura Francis sold 1,901 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $23.18, for a total value of $44,065.18. Following the completion of the sale, the chief executive officer owned 351,275 shares in the company, valued at approximately $8,142,554.50. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Laura Francis also recently made the following trade(s):

  • On Monday, November 16th, Laura Francis sold 14,953 shares of SiBone stock. The stock was sold at an average price of $23.33, for a total transaction of $348,853.49.
  • On Wednesday, November 4th, Laura Francis sold 75,000 shares of SiBone stock. The shares were sold at an average price of $25.30, for a total transaction of $1,897,500.00.
  • On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The stock was sold at an average price of $20.05, for a total value of $762,020.30.
  • On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64.
  • On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.
  • On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Trading Up 1.6%

Shares of SiBone stock traded up $0.38 during trading on Wednesday, reaching $23.54. 1,120,107 shares of the company were exchanged, compared to its average volume of 644,914. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64. The business has a 50-day moving average price of $20.56 and a 200-day moving average price of $16.85. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. Sell-side analysts anticipate that SiBone will post -0.34 EPS for the current fiscal year.

Institutional Trading of SiBone

A number of institutional investors and hedge funds have recently bought and sold shares of SIBN. Versant Capital Management Inc lifted its stake in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock worth $29,000 after acquiring an additional 887 shares during the period. State of Wyoming increased its position in SiBone by 70.8% in the 1st quarter. State of Wyoming now owns 10,832 shares of the company's stock valued at $137,000 after buying an additional 4,490 shares in the last quarter. Inceptionr LLC acquired a new position in shares of SiBone during the first quarter worth approximately $156,000. ADAR1 Capital Management LLC acquired a new position in shares of SiBone during the first quarter valued at about $159,000. Finally, Pathstone Holdings LLC purchased a new stake in SiBone in the 3rd quarter valued at $346,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on SIBN shares. Needham & Company LLC cut their price objective on shares of SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Tuesday, November 3rd. Wall Street Zen upgraded SiBone from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. Weiss Ratings raised SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Citigroup reaffirmed a "market outperform" rating on shares of SiBone in a report on Tuesday, November 3rd. Finally, Truist Financial upped their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, October 14th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, SiBone presently has an average rating of "Moderate Buy" and a consensus price target of $25.00.

View Our Latest Stock Report on SiBone

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Featured Stories

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SiBone Right Now?

Before you consider SiBone, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.

While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines